Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Clinical evaluation of adriamycin, a new antitumour antibiotic.

Literature DB >> 5257148

Clinical evaluation of adriamycin, a new antitumour antibiotic.

G Bonadonna, S Monfardini, M De Lena, F Fossati-Bellani.

Abstract

Adriamycin, a new antitumour antibiotic of the anthracycline group with a structural formula very similar to daunorubicin, has proved to have potent tumour-growth-inhibiting properties, and to be particularly effective in childhood malignancies. Though adriamycin produces a higher percentage of side-effects than daunorubicin-namely, stomatitis and alopecia-a lower dosage may be used for therapy.

Entities: Chemical Disease

Mesh：

Substances：

Year: 1969 PMID： 5257148 PMCID： PMC1984262 DOI： 10.1136/bmj.3.5669.503

Source DB: PubMed Journal: Br Med J ISSN： 0007-1447

10 in total

1. Meaningful clinical classification of therapeutic responses to anticancer drugs.

Authors: D A KARNOFSKY
Journal: Clin Pharmacol Ther Date: 1961 Nov-Dec Impact factor: 6.875

2. Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia.

Authors: C Tan; H Tasaka; K P Yu; M L Murphy; D A Karnofsky
Journal: Cancer Date: 1967-03 Impact factor: 6.860

3. Daunorubicin in the treatment of acute myelocytic leukaemia.

Authors: M Boiron; M Weil; C Jacquillat; J Tanzer; D Levy; C Sultan; J Bernard
Journal: Lancet Date: 1969-02-15 Impact factor: 79.321

4. Daunorubicin in acute myelocytic leukaemia.

Authors: J S Malpas; R B Scott
Journal: Lancet Date: 1969-03-01 Impact factor: 79.321

5. Cardiac toxicity of daunorubicin.

Authors: G Bonadonna; S Monfardini
Journal: Lancet Date: 1969-04-19 Impact factor: 79.321

6. Cardiac toxicity of daunorubicin.

Authors: A M Marmont; E Damasio; F Rossi
Journal: Lancet Date: 1969-04-19 Impact factor: 79.321

7. [Cardiac complications observed during treatment with rubidomycin].

Authors: C Macrez; H Marneffe-Lebrequier; J Ripault; J P Clauvel; C Jacquillat; M Weil
Journal: Pathol Biol Date: 1967-10

8. Adriamycin (NSC-123,127): a new antibiotic with antitumor activity.

Authors: A Di Marco; M Gaetani; B Scarpinato
Journal: Cancer Chemother Rep Date: 1969-02

9. Rubidomycin in acute leukaemia in adults.

Authors: J S Malpas; R B Scott
Journal: Br Med J Date: 1968-07-27

10. [Therapy with daunomycin in chronic lymphoproliferative diseases].

Authors: G Bonadonna; S Monfardini; A Guindani
Journal: Tumori Date: 1968 Nov-Dec

10 in total

49 in total

1. Nicotinamide riboside promotes autolysosome clearance in preventing doxorubicin-induced cardiotoxicity.

Authors: Dong Zheng; Yi Zhang; Ming Zheng; Ting Cao; Grace Wang; Lulu Zhang; Rui Ni; Joseph Brockman; Huiting Zhong; Guo-Chang Fan; Tianqing Peng
Journal: Clin Sci (Lond) Date: 2019-07-15 Impact factor: 6.124

2. Effects of pirarubicin, an antitumor antibiotic, on the cardiovascular system.

Authors: S Hirano; N Agata; Y Hara; H Iguchi; M Shirai; H Tone; N Urakawa
Journal: Cancer Chemother Pharmacol Date: 1991 Impact factor: 3.333

3. Multiscale and Translational Quantitative Systems Toxicology, Pharmacokinetic-Toxicodynamic Modeling Analysis for Assessment of Doxorubicin-Induced Cardiotoxicity.

Authors: Tanaya R Vaidya; Hardik Mody; Yesenia L Franco; Ashley Brown; Sihem Ait-Oudhia
Journal: AAPS J Date: 2021-01-06 Impact factor: 4.009

Clinical evaluation of adriamycin, a new antitumour antibiotic.

1. Meaningful clinical classification of therapeutic responses to anticancer drugs.

2. Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia.

3. Daunorubicin in the treatment of acute myelocytic leukaemia.

4. Daunorubicin in acute myelocytic leukaemia.

5. Cardiac toxicity of daunorubicin.

6. Cardiac toxicity of daunorubicin.

7. [Cardiac complications observed during treatment with rubidomycin].

8. Adriamycin (NSC-123,127): a new antibiotic with antitumor activity.

9. Rubidomycin in acute leukaemia in adults.

10. [Therapy with daunomycin in chronic lymphoproliferative diseases].

1. Nicotinamide riboside promotes autolysosome clearance in preventing doxorubicin-induced cardiotoxicity.

2. Effects of pirarubicin, an antitumor antibiotic, on the cardiovascular system.

3. Multiscale and Translational Quantitative Systems Toxicology, Pharmacokinetic-Toxicodynamic Modeling Analysis for Assessment of Doxorubicin-Induced Cardiotoxicity.

Review 4. Anthracycline analogs: the past, present, and future.

5. [Circumoperative and postoperative cytostatic therapy in neuroblastomas and Wilms tumors in childhood].

Review 6. Cancer chemotherapy--the first twenty-five years.

Review 7. Cancer chemotherapy: past, present, and future--Part I.

8. Adriamycin in the treatment of acute leukaemia.

9. Toxicological evaluation of imipramine in combination with adriamycin and strophanthin.

10. Chemotherapy for early-stage breast cancer: a brief history.